Clearbridge Has Increased Keryx Biopharmaceuticals (KERX) Stake By $942,060; Cvd Equipment (CVV) Shorts Up By 0.6%

January 14, 2018 - By Maria Brooks

Cvd Equipment Corporation (NASDAQ:CVV) had an increase of 0.6% in short interest. CVV’s SI was 388,100 shares in January as released by FINRA. Its up 0.6% from 385,800 shares previously. With 26,500 avg volume, 15 days are for Cvd Equipment Corporation (NASDAQ:CVV)’s short sellers to cover CVV’s short positions. The SI to Cvd Equipment Corporation’s float is 7.44%. The stock increased 1.10% or $0.12 during the last trading session, reaching $11.06. About 24,459 shares traded or 16.38% up from the average. CVD Equipment Corporation (NASDAQ:CVV) has risen 68.19% since January 14, 2017 and is uptrending. It has outperformed by 51.49% the S&P500.

Clearbridge Llc increased Keryx Biopharmaceuticals Inc (KERX) stake by 9.15% reported in 2017Q3 SEC filing. Clearbridge Llc acquired 134,580 shares as Keryx Biopharmaceuticals Inc (KERX)’s stock rose 24.11%. The Clearbridge Llc holds 1.61 million shares with $11.40 million value, up from 1.47 million last quarter. Keryx Biopharmaceuticals Inc now has $557.96 million valuation. The stock decreased 1.27% or $0.06 during the last trading session, reaching $4.68. About 822,128 shares traded. Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has risen 13.56% since January 14, 2017 and is uptrending. It has underperformed by 3.14% the S&P500.

Since August 16, 2017, it had 0 insider purchases, and 5 selling transactions for $136,430 activity. On Friday, December 8 CHARLES GLEN R sold $49,108 worth of CVD Equipment Corporation (NASDAQ:CVV) or 4,402 shares. LINSS WILLIAM S sold $44,080 worth of stock. On Friday, December 8 the insider ARAGON STEVEN sold $25,890. GUNTHER CONRAD J JR sold $5,580 worth of stock or 500 shares.

Investors sentiment decreased to 1.67 in 2017 Q3. Its down 1.33, from 3 in 2017Q2. It dived, as 2 investors sold CVD Equipment Corporation shares while 4 reduced holdings. 3 funds opened positions while 7 raised stakes. 1.29 million shares or 6.25% more from 1.21 million shares in 2017Q2 were reported. Northern invested in 0% or 12,511 shares. 288,700 are held by Awm Investment Inc. Oberweis Asset Inc accumulated 20,000 shares. Royal National Bank Of Canada has 1 shares. Dimensional Fund Advisors Lp holds 41,442 shares or 0% of its portfolio. Vanguard Grp has 0% invested in CVD Equipment Corporation (NASDAQ:CVV). Keybank Association Oh reported 80,500 shares. 73,590 are owned by Janney Montgomery Scott. Fifth Third Bank & Trust has 0% invested in CVD Equipment Corporation (NASDAQ:CVV) for 500 shares. Bank & Trust Of America De holds 0% or 766 shares. Deutsche Bank & Trust Ag, Germany-based fund reported 29,691 shares. Renaissance Ltd holds 128,000 shares. 268 were accumulated by Tower Research Ltd Liability Corporation (Trc). Morgan Stanley reported 5,829 shares. Wynnefield Capital Inc holds 45,861 shares.

CVD Equipment Corporation develops, makes, and sells equipment and process solutions used to develop and manufacture materials and coatings for research and industrial applications in the United States and internationally. The company has market cap of $70.89 million. The firm operates through two divisions, CVD/First Nano and Stainless Design Concepts. It has a 15.71 P/E ratio. It offers chemical vapor deposition systems for use in the research, development, and manufacture of aerospace and medical components, semiconductors, LEDs, carbon nanotubes, nanowires, solar cells, MEMS, and other industrial applications; and rapid thermal processing systems for use in implant activation, oxidation, silicide formation, and other processes.

Since October 5, 2017, it had 0 buys, and 9 insider sales for $84,165 activity. Adams Brian also sold $4,530 worth of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) on Thursday, October 5. 4,055 shares valued at $24,452 were sold by Madison Greg on Monday, October 30. The insider Neylan John F. sold 1,179 shares worth $7,699. 2,582 shares were sold by Holmes Scott A, worth $15,569.

Investors sentiment decreased to 1.5 in 2017 Q3. Its down 0.47, from 1.97 in 2017Q2. It dropped, as 12 investors sold KERX shares while 26 reduced holdings. 14 funds opened positions while 43 raised stakes. 75.60 million shares or 1.12% less from 76.46 million shares in 2017Q2 were reported. Rice Hall James & Associates Limited Liability reported 1.60 million shares. Boston Partners owns 409,051 shares. Monarch Prtnrs Asset Mgmt Ltd has 0.47% invested in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). 5.99 million were accumulated by Blackrock Inc. Baldwin Brothers Ma invested in 43,300 shares. Clearbridge Invests Ltd Liability Corporation stated it has 8,635 shares or 0% of all its holdings. Parametric Portfolio Assoc Limited Liability Corporation reported 0% in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Blair William & Company Il reported 192,400 shares stake. State Of Wisconsin Invest Board has invested 0% of its portfolio in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Aqr Cap Mgmt Ltd Limited Liability Company holds 0% in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) or 28,069 shares. Moreover, Tower Limited Liability Corporation (Trc) has 0.01% invested in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) for 9,868 shares. Goldman Sachs Grp Inc owns 708,053 shares. Geode Mngmt Ltd Liability owns 893,176 shares. Prudential Financial, New Jersey-based fund reported 10,385 shares. Usca Ria Ltd Limited Liability Company has invested 0.02% in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX).

Clearbridge Llc decreased Hanesbrands Inc (NYSE:HBI) stake by 80,897 shares to 1.58 million valued at $38.83M in 2017Q3. It also reduced Alexion Pharmaceuticals Inc (NASDAQ:ALXN) stake by 196,158 shares and now owns 630,682 shares. Adient Plc was reduced too.

Among 15 analysts covering Keryx Biopharmaceuticals (NASDAQ:KERX), 6 have Buy rating, 2 Sell and 7 Hold. Therefore 40% are positive. Keryx Biopharmaceuticals had 36 analyst reports since July 23, 2015 according to SRatingsIntel. On Thursday, July 27 the stock rating was maintained by Cowen & Co with “Hold”. The firm has “Buy” rating given on Thursday, July 23 by TH Capital. The stock of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9. Zacks upgraded Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) on Friday, August 28 to “Sell” rating. The stock has “Hold” rating by Cowen & Co on Friday, June 16. The rating was maintained by Maxim Group on Thursday, July 27 with “Buy”. The rating was initiated by Citigroup on Thursday, September 3 with “Sell”. The stock has “Buy” rating by Maxim Group on Tuesday, March 29. BTIG Research maintained the shares of KERX in report on Thursday, August 6 with “Sell” rating. The stock of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) earned “Hold” rating by Stifel Nicolaus on Wednesday, November 8.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: